Trikafta, a cystic fibrosis drug approved by the FDA in 2019, exemplifies successful public-private collaboration in biomedical innovation, significantly improving outcomes for patients. Following its initial approval for patients over 12, FDA guidelines expanded access to younger children, allowing many to manage a previously fatal disease. The drug's development, backed by the NIH, the Cystic Fibrosis Foundation, and Vertex, showcases the importance of federal support in advancing medical research. The experiences of patients like the Vought family highlight the transformative impact of Trikafta on the lives of those with CF, marking a major milestone in medical innovation.
Today our little one starts #trikafta. Beyond grateful for this miracle drug.... We're extremely grateful to live in a nation that leads the way on medical innovation.
Over the next six years, the FDA allowed children older than 2 to take Trikafta and included a wider range of genetic mutations on the label, making the drug available to tens of thousands of patients with CF.
Collection
[
|
...
]